Dr. Thomas Petry

Dr. Thomas Petry is the Managing Director and owner of ToxMinds BVBA. He has 25 years of industry, consulting and research experience in the human safety assessment of chemical exposures occurring at the workplace, through their use or presence in consumer products or via the environment.

Thomas founded ToxMinds in early 2007, following five years as Senior Director at the Weinberg Group LLC, and prior to that at Procter & Gamble. Technically, Thomas is considered to be an expert in supporting chemical safety and registrations on the basis of non-animal alternatives (e.g., SAR/analogue-based read across justifications) and has been invited to give presentations on this subject at technical workshops organised by the European Chemicals Agency (ECHA), industry associations and scientific organisations, including the US Society of Toxicology (SOT). At the regulatory level, he has substantial experience with REACH, the Biocidal Products Regulation, the Cosmetics Regulation as well as the CLP Regulation.

Thomas has a Diploma in Chemistry from the Technical University of Darmstadt, Germany, and a Ph.D. in Toxicology from the Institute of Toxicology of the Swiss Federal Institute of Technology (ETH) in Zurich. He is a European Registered Toxicologist (ERT) as well as a Diplomate of the American Board of Toxicology (DABT).

Languages: EN, DE

CONTACT

Dr. Thomas Petry, ERT, DABT
Managing Director

Phone: +32 (0)2 762 91 45
Email: contact me

SPECIALITIES

Chemicals, Biocides, Cosmetics and consumer products, Pharma

Human health risk assessment, Predictive toxicology, Integrated approaches to testing and assessment (IATA), Skin sensitization, Endocrine disruption (Human health), Consortium management

• Assessment of the skin sensitisation hazard of functional polysiloxanes and silanes in the SENS-IS assay
  Petry T, Bosch A,Koraïchi-Emeriau F, Eigler D, Germaine P, Seidel S. Regulatory Toxicology and Pharmacology 2018, 98:209-214.
• Review of data on the dermal penetration of mineral oils and waxes used in cosmetic applications.
  Petry T, Bury D, Fautz R, Hauser M, Huber B, Markowetz A, Mishra S, Rettinger K, Schuh W, Teichert T. Toxicology Letters 2017, 280:70-78.
• Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes.
  Petry T, Bosch A, Coste X, Eigler D, Germain P, Seidel S, Jean PA. Regulatory Toxicology and Pharmacology 2017, 84:64-76.
• Case studies putting the decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping) into practice.
  Arts JH, Irfan M-A, Keene AM, Kreiling R, Lyon D, Maier M, Michel K, Neubauer N, Petry T, Sauer UG: Regulatory Toxicology and Pharmacology 2016, 76:234-261.